last authored:
last reviewed:
Fabry Disease is due to a mutation in the enzyme ceramide trihexosidase, or alpha-galactosidease-A, responsible for lipid metabolism. It affects 1:40,000 males.
a simple case introducing clincial presentation and calling for a differential diagnosis to get students thinking.
The gene is carried on the X-chromosome, meaning males who inherit the mutation will develop the disease while daughters have a 50% chance of being a carrier. However, some women may also have symptoms of the disease.
Mutation results in insufficient lipid breakdown, resulting in deposition in the eyes, kidneys, autonomic nervous system, and cardiovascular system.
Symptoms usually begin in childhood or adolescence. These can include:
Small, reddish-purple angiokeratomas may be present on the skin, most densely from the umbilicus to the knees.
Eye manifestations can include cloudiness of the cornea, though vision tends not to be affected.
Enzyme replacement can help slow progression.
Anticonvulsants such as phenytoin or carbamazepine can help with pain in hands and feet.
Metaclopramide can help delay gastric emptying.
Kidney failure can lead to dialysis or transplantation.
Fabry disease has diverse manifestations, requiring treatment from a variety of health care professionals.
Survival into adult is common, but strokes, heart disease, and kidney failure often begin between ages of 30-45.
Patient and Family Organizations include:
Fabry Support and Information Group (outside link)
National Tay-Sachs and Allied Diseases Association (outside link)
Video explaining lysosomal disease
authors:
reviewers: